1. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial
- Author
-
Ruel, Theodore D, Acosta, Edward P, Liu, Jessica P, Gray, Kathryn P, George, Kathleen, Montañez, Nicole, Popson, Stephanie, Buchanan, Ann M, Bartlett, Mattie, Dayton, Dale, Anthony, Patricia, Brothers, Cynthia, Vavro, Cynthia, Singh, Rajendra, Koech, Lucy, Vhembo, Tichaona, Mmbaga, Blandina T, Pinto, Jorge A, Dobbels, Els FM, Archary, Moherndran, Chokephaibulkit, Kulkanya, Ounchanum, Pradthana, Deville, Jaime G, Hazra, Rohan, Townley, Ellen, Wiznia, Andrew, team, IMPAACT P1093, Carter, Michele F, Mansky, Hannah, Ferreira, Flavia F, Romeiro, Juliana, D'Angelo, Jessica, Williams, Ruth, Jundi, Fernanda, Cruz, Maria Letícia Santos, Sidi, Claude Leon, Kataike, Hajira, Owor, Maxensia, Ahimbisibwe, Grace Miriam, van Rensburg, Anita Janse, Andrea, Catherine V, Ponatshego, Ponego L, Budu, Marian, Tirelo, Lesedi, Masheto, Gaerolwe R, Raesi, Mpho S, Ramogodiri, Moakanyi, Chanthong, Jiraporn, Khamrong, Chintana, Aurpibul, Linda, Fairlie, Lee, Patel, Faeezah, Soma-Kashiram, Hamisha, Hanley, Sherika, Govender, Vani, Sturzbecher, Fernanda Tomé, Cervi, Maria Célia, Njau, Boniface, Matibe, Petronilla, Mukonowenzou, Ruvimbo, Marozva, Catherine C, Keter, Winnie C, Bii, Priscilla C, Cressey, Tim R, Sukrakanchana, Pra-ornsuda, Rungmaitree, Supattra, Pilotto, Jose Henrique, Fernandes, Luis Eduardo, and Gomes, Ivete Martins
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Pediatric ,Sexually Transmitted Infections ,HIV/AIDS ,Prevention ,Clinical Trials and Supportive Activities ,Women's Health ,Clinical Research ,Pediatric AIDS ,Infectious Diseases ,6.1 Pharmaceuticals ,5.1 Pharmaceuticals ,6.2 Cellular and gene therapies ,Infection ,Good Health and Well Being ,Adolescent ,Adult ,Antiviral Agents ,Child ,Child ,Preschool ,Female ,HIV Infections ,HIV Integrase Inhibitors ,HIV Seropositivity ,HIV-1 ,Heterocyclic Compounds ,3-Ring ,Humans ,Infant ,Male ,Oxazines ,Piperazines ,Pyridones ,RNA ,Tablets ,IMPAACT P1093 team ,Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundSafe and potent antiretroviral medications in child-friendly formulations are needed to treat young children living with HIV-1. We aimed to select dosing for a dispersible tablet formulation of dolutegravir that achieved pharmacokinetic exposures similar to those in adults, and was safe and well tolerated in young children.MethodsInternational Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) P1093 is a phase 1-2 ongoing multicentre, open-label, non-comparative study of dolutegravir. A 5 mg dispersible tablet formulation of dolutegravir was studied in children aged 4 weeks to less than 6 years old, weighing at least 3 kg, with HIV RNA of greater than 1000 copies per mL and no previous treatment with integrase strand transfer inhibitor recruited from IMPAACT clinical research sites in Africa, the Americas, and Asia. Doses were selected on the basis of intensive pharmacokinetic evaluation on days 5-10, with safety and tolerability assessed up to 48 weeks. The primary objectives of this study are to evaluate the pharmacokinetics of dolutegravir in combination with optimised background therapy and to establish the dose of dolutegravir that achieves the targeted 24-h trough concentration and 24-h area under the curve for infants, children, and adolescents with HIV-1, to establish the safety and tolerability of dolutegravir at 24 and 48 weeks, and to select a dose that achieves similar exposure to the dolutegravir 50 mg once daily dose in adults. This analysis included participants treated with the proposed dose of dolutegravir dispersible tablets in two stages for each of three age cohorts. This trial is registered at ClinicalTrials.gov (NCT01302847) and is ongoing.FindingsWe recruited 181 participants from April 20, 2011, to Feb 19, 2020; of these, 96 received dolutegravir dispersible tablets. This analysis included 73 (35, 48% female) participants who received the final proposed dose with median (range) age of 1 year (0·1 to 6·0), weight (minimum-maximum) of 8·5 kg (3·7 to 18·5), plasma HIV-1 RNA concentration of 4·2 log10 copies per mL (2·1 to 7·0), and CD4% of 24·0% (0·3 to 49·0); 64 (87·7%) were treatment-experienced. The selected dose within each age cohort (≥2 years to
- Published
- 2022